{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:24:32Z","timestamp":1780316672382,"version":"3.54.1"},"reference-count":28,"publisher":"Japan Atherosclerosis Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,1,1]]},"DOI":"10.5551\/jat.60921","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T22:09:57Z","timestamp":1647641397000},"page":"74-86","source":"Crossref","is-referenced-by-count":6,"title":["Acute Cholesterol-Lowering Effect of Exendin-4 in &lt;i&gt;Ldlr&lt;\/i&gt;&lt;sup&gt;\u2212\/\u2212&lt;\/sup&gt; and C57BL\/6J Mice"],"prefix":"10.5551","volume":"30","author":[{"given":"Mika","family":"Hori","sequence":"first","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"},{"name":"Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University"},{"name":"Department of Endocrinology, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"},{"name":"Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University"},{"name":"Department of Endocrinology, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakagami","sequence":"additional","affiliation":[{"name":"Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE and Wheeler MB: The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes, 2002; 51 Suppl 3: S434-442","DOI":"10.2337\/diabetes.51.2007.S434"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Yamato E, Noma Y, Tahara Y, Ikegami H, Yamamoto Y, Cha T, Yoneda H, Ogihara T, Ohboshi C, Hirota M and Shima K: Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets. Biochem Biophys Res Commun, 1990; 167: 431-437","DOI":"10.1016\/0006-291X(90)92041-W"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P and Dandona P: Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract, 2007; 13: 444-450","DOI":"10.4158\/EP.13.5.444"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME and Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin, 2008; 24: 275-286","DOI":"10.1185\/030079907X253870"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Horton ES, Silberman C, Davis KL and Berria R: Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care, 2010; 33: 1759-1765","DOI":"10.2337\/dc09-2062"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC and Reaven PD: Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis, 2010; 212: 217-222","DOI":"10.1016\/j.atherosclerosis.2010.05.028"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hasegawa Y, Hori M, Nakagami T, Harada-Shiba M, Uchigata Y: Glucagon-like peptide-1 receptor agonists reduced the LDL-cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. J Clin Lipidol, 2018; 12: 62-69","DOI":"10.1016\/j.jacl.2017.11.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yang SH, Xu RX, Cui CJ, Wang Y, Du Y, Chen ZG, Yao YH, Ma CY, Zhu CG, Guo YL, Wu NQ, Sun J, Chen BX and Li JJ: Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db\/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol, 2018; 17: 48","DOI":"10.1186\/s12933-018-0689-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Rakipovski G, Rolin B, N\u00f8hr J, Klewe I, Frederiksen KS, Augustin R, Hecksher-S\u00f8rensen J, Ingvorsen C, Polex-Wolf J and Knudsen LB: The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(-\/-) and LDLr(-\/-) Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci, 2018; 3: 844-857","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Eng J, Kleinman WA, Singh L, Singh G and Raufman JP: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem, 1992; 267: 7402-7405","DOI":"10.1016\/S0021-9258(18)42531-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Folch J, Lees M and Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem, 1957; 226: 497-509","DOI":"10.1016\/S0021-9258(18)64849-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yabe D, Brown MS and Goldstein JL: Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci U S A, 2002; 99: 12753-12758","DOI":"10.1073\/pnas.162488899"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hubbert ML, Zhang Y, Lee FY and Edwards PA: Regulation of hepatic Insig-2 by the farnesoid X receptor. Mol Endocrinol, 2007; 21: 1359-1369","DOI":"10.1210\/me.2007-0089"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hwang S, Nguyen AD, Jo Y, Engelking LJ, Brugarolas J and DeBose-Boyd RA: Hypoxia-inducible factor 1\u03b1 activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J Biol Chem, 2017; 292: 9382-9393","DOI":"10.1074\/jbc.M117.788562"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Qin X, Xie X, Fan Y, Tian J, Guan Y, Wang X, Zhu Y and Wang N: Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology, 2008; 48: 432-441","DOI":"10.1002\/hep.22334"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Vock C, D\u00f6ring F and Nitz I: Transcriptional regulation of HMG-CoA synthase and HMG-CoA reductase genes by human ACBP. Cell Physiol Biochem, 2008; 22: 515-524","DOI":"10.1159\/000185525"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jung D, Inagaki T, Gerard RD, Dawson PA, Kliewer SA, Mangelsdorf DJ and Moschetta A: FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J Lipid Res, 2007; 48: 2693-2700","DOI":"10.1194\/jlr.M700351-JLR200"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ and Kliewer SA: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab, 2005; 2: 217-225","DOI":"10.1016\/j.cmet.2005.09.001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Gardes C, Chaput E, Staempfli A, Blum D, Richter H and Benson GM: Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr -\/- mice versus hamsters. J Lipid Res, 2013; 54: 1283-1299","DOI":"10.1194\/jlr.M033423"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Madsen MSA, Holm JB, Pallej\u00e0 A, Wismann P, Fabricius K, Rigbolt K, Mikkelsen M, Sommer M, Jelsing J, Nielsen HB, Vrang N and Hansen HH: Metabolic and gut microbiome changes following GLP-1 or dual GLP-1\/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep, 2019; 9: 15582","DOI":"10.1038\/s41598-019-52103-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kirby RJ, Howles PN and Hui DY: Rate of gastric emptying influences dietary cholesterol absorption efficiency in selected inbred strains of mice. J Lipid Res, 2004; 45: 89-98","DOI":"10.1194\/jlr.M300148-JLR200"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Parlevliet ET, Wang Y, Geerling JJ, Schroder-Van der Elst JP, Picha K, O\u2019Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H and Rensen PC: GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE<sup>\uff0a<\/sup>3-Leiden mice. PLoS One, 2012; 7: e49152","DOI":"10.1371\/journal.pone.0049152"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW and Lee WY: Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6J mice. PLoS One, 2012; 7: e31394","DOI":"10.1371\/journal.pone.0031394"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Yin QH, Zhang R, Li L, Wang YT, Liu JP, Zhang J, Bai L, Cheng JQ, Fu P and Liu F: Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice. J Biol Chem, 2016; 291: 26487-26501","DOI":"10.1074\/jbc.M116.730564"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Taher J, Baker CL, Cuizon C, Masoudpour H, Zhang R, Farr S, Naples M, Bourdon C, Pausova Z and Adeli K: GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Mol Metab, 2014; 3: 823-833","DOI":"10.1016\/j.molmet.2014.09.005"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, Streutker C, Holland D, Cao X, Baggio LL and Drucker DJ: GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice. Endocrinology, 2013; 154: 127-139","DOI":"10.1210\/en.2012-1937"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ionut V, Hucking K, Liberty IF and Bergman RN: Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia, 2005; 48: 967-975","DOI":"10.1007\/s00125-005-1709-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Khound R, Taher J, Baker C, Adeli K and Su Q: GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance. Arterioscler Thromb Vasc Biol, 2017; 37: 2252-2259","DOI":"10.1161\/ATVBAHA.117.310251"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/1\/30_60921\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:49:21Z","timestamp":1715316561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/1\/30_60921\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.60921","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"article-number":"60921"}}